Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03702725 · OUTCOME

Progression Free Survival

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma · Source last updated 2026-01-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
days
Interval / dispersion
95% Confidence Interval
Time frame
34 Months

What was measured

Progression-free survival time is the time from study entry to the documentation of disease progression or death due to any cause.

Analysis population: Per-protocol - all eligible patients who initiated protocol treatment regardless of DL received

Groups in this outcome

Dose Level 1 Starting Cohort

Ibrutinib 560 mg on Days 1-28, * Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days

Dose Level 2

Ibrutinib 560 mg on Days 1-28, * Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days

Dose Level 3

Ibrutinib 840 mg on Days 1-28, * Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dose Level 1 Starting Cohort6
Dose Level 23
Dose Level 34

Reported measurements

Source class 1
Values in days · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Dose Level 1 Starting Cohort215Not reported56NAThere are not enough events to calculate upper confidence bound.
Dose Level 2106Not reported85NAThere are not enough events to calculate upper confidence bound.
Dose Level 3102Not reported56NAThere are not enough events to calculate upper confidence bound.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        There are not enough events to calculate upper confidence bound.
        group Id
        OG000
        lower Limit
        56
        upper Limit
        NA
        value
        215
      2. comment
        There are not enough events to calculate upper confidence bound.
        group Id
        OG001
        lower Limit
        85
        upper Limit
        NA
        value
        106
      3. comment
        There are not enough events to calculate upper confidence bound.
        group Id
        OG002
        lower Limit
        56
        upper Limit
        NA
        value
        102
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      4
    units
    Participants
description
Progression-free survival time is the time from study entry to the documentation of disease progression or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Ibrutinib 560 mg on Days 1-28, * Lenalidomide 15 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days
    id
    OG000
    title
    Dose Level 1 Starting Cohort
  2. description
    Ibrutinib 560 mg on Days 1-28, * Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days
    id
    OG001
    title
    Dose Level 2
  3. description
    Ibrutinib 840 mg on Days 1-28, * Lenalidomide 25 mg on Days 1-21 Dexamethasone 40 mg on Days 1,8,15, 22 * Every 28 days
    id
    OG002
    title
    Dose Level 3
param Type
MEDIAN
population Description
Per-protocol - all eligible patients who initiated protocol treatment regardless of DL received
reporting Status
POSTED
time Frame
34 Months
title
Progression Free Survival
type
SECONDARY
unit Of Measure
days

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice